(Q43906898)

English

Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.

scientific article published on 12 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Peter Mu-Hsin Chang

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Cheng-Hwai Tzeng

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Ming-Huang Chen

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Chao-Jung Tsao

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Wei-Shuo Hwang

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Yi-Fang Chang

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Shyue-Yih Chang

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Muh-Hwa Yang

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

12 April 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

68

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1477-1484

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

https://scigraph.springernature.com/pub.10.1007/s00280-011-1645-5

0 references

Molecular pathogenesis of head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Clinical pharmacokinetics of docetaxel.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1645-5

21 January 2018

Identifiers

10.1007/S00280-011-1645-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Dimensions Publication ID

0 references

release_syl4fnsx7fewbalfepyzjghn3a

1 reference

https://api.fatcat.wiki/v0/release/syl4fnsx7fewbalfepyzjghn3a

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21484308%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43906898&oldid=2104309739"